NovoCure Limited

As of June 30, 2026, NovoCure Ltd. Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh carries a market capitalization of 8.95B, placing it among publicly traded companies globally. Its enterprise value stands at 7.88B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

NovoCure Ltd. Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, NovoCure Ltd. Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh has 1.26B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.42, and the price-to-book ratio stands at 5.12.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 7.88B versus a market cap of 8.95B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, NovoCure Ltd. Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh maintains a current ratio of 2.89, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, NovoCure Ltd. Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh posted a negative return on equity (ROE) of -43.22, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -14.56, reflecting losses generated across the asset base. The company generates approximately 2.29M in revenue per employee across its workforce of 1,575.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.05 indicates how many times NovoCure Ltd. Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, NovoCure Ltd. Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh recorded an income tax benefit of -21.30M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -789.23M and -767.93M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 19, 2026, NovoCure Ltd. Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh's stock has declined approximately 5.58% over the past 52 weeks. The 50-day moving average sits at 8.09, while the 200-day moving average is 9.59.

Over the twelve months ended June 30, 2026, NovoCure Ltd. Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh generated 3.61B in revenue and converted that into -767.93M in net income, yielding earnings per share of -0.63. EBITDA reached -713.76M, while operating income came in at -798.07M.

As of June 30, 2026, NovoCure Ltd. Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh holds 2.28B in cash and equivalents against 1.21B in total debt, resulting in a net debt position of 528.22M. Total book value stands at 1.75B, with working capital of 2.16B providing operational flexibility.

NovoCure Ltd. Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh produced -14.55M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -116.92M in capital expenditures, free cash flow totaled -131.47M - equivalent to -0.11 per share.

Over the twelve months ended June 30, 2026, NovoCure Ltd. Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh posted a gross margin of 76.13, reflecting its pricing power and cost economics. The operating margin of -22.08 and net profit margin of -21.25 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.51: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 26.26, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to NovoCure Ltd. Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh shareholders.

As of June 30, 2026, NovoCure Ltd. Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh has an Altman Z-Score of 0.72, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.